A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma

NCT02852655 · clinicaltrials.gov ↗
PHASE1
Phase
ACTIVE_NOT_RECRUITING
Status
60
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Dana-Farber Cancer Institute

Collaborators